Dupuytren's contracture (DC) is a common benign soft tissue disease of the hand affecting millions of people in northern Europe and Northern America. It causes thickening of palmar fascia (connective tissue of the hand) and results in flexion contracture of fingers. The treatment is division of thickened connective tissue cord in operation, or division with a needle or dissolving it enzymatically (a drug). Currently, we do not know, which treatment yields best outcomes (hand function, satisfaction) with least harms and costs.
The aim of the trial is to investigate three treatment strategies in long term to identify the most effective and cost-effective treatment in 5-years follow-up.
We are performing a national trial in six hospitals in Finland and will recruit 287 participants. We will measure outcomes and costs at 3-months, 2-years, 5-years and 10-years. Our study will inform patients and society which treatment strategy should be adapted to treat this condition.